Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 11Genitourinary 8Dermatologic 6Thoracic 5Breast 5Gynecologic 4Tumor-Agnostic 3Lymphoid 3Head & Neck 3Sarcoma 1Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Recurrence 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × ALT-803 × Other hematologic neoplasm × Clear all
NCT02384954 2024-07-03

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Altor BioScience

Phase 1/2 Terminated
43 enrolled 15 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡